Etripamil
Important Notice: For research use only. We do not sell to patients.
Not your Region? View all Distributors
Important Notice: For research use only. We do not sell to patients.
Not your Region? View all Distributors
Discription | Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist with a rapid onset of action designed for intranasal administration, used to treat Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells. | ||
---|---|---|---|
Targets |
|
Catalog Num | A18082 |
---|---|
Formula | C27H36N2O4 |
Molecular Weight | 452.6 |
CAS Number | 1593673-23-4 |
SMILES | O=C(OC)C1=CC=CC(CCN(CCC[C@](C2=CC=C(OC)C(OC)=C2)(C#N)C(C)C)C)=C1 |
Synonyms | (-)-MSP-2017; MSP-2017; MSP 2017; MSP2017; MSP-2017A; MSP-2017B; Etripamil |
Storage | Store lyophilized at -20ºC, keep desiccated. |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2